Skyrizi vs Stelara at a glance: Skyrizi (risankizumab) and Stelara (ustekinumab) are widely prescribed biologics in dermatology and gastroenterology. The core difference: Skyrizi selectively blocks interleukin-23 (its p19 subunit), while Stelara blocks both IL-12 and IL-23 (the shared p40 subunit). Both are FDA-approved for plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. Which one is “better” depends on your diagnosis, your history, and your doctor, not on marketing.
The Skyrizi vs Stelara comparison is one patients ask about constantly, because both are among the most prescribed biologics for immune-mediated conditions. This guide answers it the way we answer every comparison: with clarity, clinical rigor, and honesty. They act on related but distinct targets, overlap across several approved uses, and differ in the evidence, the administration, and (something almost no comparison covers) the real cost in the United States.
How each biologic works: IL-23 vs IL-12/23
Both drugs are monoclonal antibodies that “switch off” inflammatory signals, but they don’t target the same switch.
Skyrizi (risankizumab): selective IL-23 (p19) inhibition
Skyrizi binds specifically to the p19 subunit of interleukin-23, a cytokine central to psoriatic disease and bowel inflammation. Because it is selective, it leaves IL-12 (involved in other immune responses) intact. That selectivity underlies the recent clinical interest in IL-23 inhibitors.
Stelara (ustekinumab): dual IL-12/23 (p40) inhibition
Stelara binds the p40 subunit, which IL-12 and IL-23 share. It therefore blocks both cytokines at once. It’s a broader mechanism with a longer track record on the market, meaning years of accumulated clinical experience.
The best biologic is the one your doctor selects for your diagnosis, and then the one you can afford safely.
Approved uses: where they overlap and where they differ
Across their FDA labels, Skyrizi vs Stelara overlap in most major indications, with a few differences worth knowing before you and your doctor decide.
Plaque psoriasis and psoriatic arthritis
Both are FDA-approved for moderate-to-severe plaque psoriasis and for psoriatic arthritis. In dermatology, selective IL-23 inhibitors like Skyrizi have shown high skin-clearance rates in their trials; Stelara remains a well-established option, especially when it’s already working well.
Crohn’s disease and ulcerative colitis
Both are approved for moderate-to-severe Crohn’s disease and ulcerative colitis. This is where head-to-head evidence becomes especially relevant.
What head-to-head evidence shows: the SEQUENCE trial
Most comparisons rely on separate studies. But in Crohn’s disease there is a head-to-head trial: the SEQUENCE study (Peyrin-Biroulet et al., 2024, published in the New England Journal of Medicine), comparing risankizumab against ustekinumab in moderate-to-severe Crohn’s. A direct trial is the strongest way to compare two treatments, because it evaluates patients under the same conditions. Discuss its findings with your gastroenterologist: it’s the best basis for an informed Crohn’s decision.
Dosing and administration: what daily life looks like
In everyday use, Skyrizi vs Stelara look more alike than different, yet the practical logistics can shape which one fits your routine.
Loading dose and maintenance schedules
Both follow a pattern of an initial loading dose followed by maintenance at regular intervals. The exact schedules depend on the indication and your doctor, so we don’t give specific doses here: your prescribing team sets them for your case.
At-home injection vs in-office infusion
Practically, part of treatment can be given as a subcutaneous injection at home and, for some bowel indications, the initial phase may be an intravenous infusion in the office. The logistics (who administers it, where, and how often) are a real day-to-day difference and deserve an explicit conversation.
Side effects and monitoring to discuss with your doctor
On safety, the Skyrizi vs Stelara profiles are broadly similar. Like all immunomodulators, both can raise the risk of infections and require screening (for example, for tuberculosis) before starting. Their side-effect profiles are generally favorable, but not identical, and your history (prior infections, vaccinations, other conditions) influences which fits best. Bring a list of your history to the appointment and ask about recommended monitoring.
The U.S. cost reality and the biosimilar question
The Skyrizi vs Stelara cost picture is where many patients feel the biggest difference, and where a little planning pays off.
Why list prices are so high
Specialty biologics are complex medicines produced in living cells, and their U.S. list prices commonly reach tens of thousands of dollars per year. What you pay depends on your insurance, your formulary, and your deductible, not on the list price alone.
Stelara biosimilars (2025) and what they change
Since 2025, Stelara biosimilars (highly similar, FDA-approved versions) have arrived, introducing price competition. Their effect on what each patient pays depends on how plans and formularies adopt them; we cover this in detail in our Humira biosimilars guide.
When cost blocks the right option: exploring safe access abroad
Sometimes the problem isn’t clinical but financial: the right drug exists, but cost puts it out of reach. For patients with a valid prescription, guided, licensed, compliance-focused access abroad is one of the legitimate ways to lower that cost. It is not the only answer and must never come before safety; to understand the legal framework, read is it legal to bring medications from Mexico?
Skyrizi vs Stelara: a patient summary
Use this Skyrizi vs Stelara summary as a quick reference to bring to your next appointment.
| Skyrizi (risankizumab) | Stelara (ustekinumab) | |
|---|---|---|
| Target | Selective IL-23 (p19) | IL-12 & IL-23 (shared p40) |
| Main FDA uses | Psoriasis, psoriatic arthritis, Crohn’s, ulcerative colitis | Psoriasis, psoriatic arthritis, Crohn’s, ulcerative colitis |
| Head-to-head evidence | SEQUENCE trial in Crohn’s (NEJM, 2024) | |
| Administration | Loading + maintenance; depending on indication, home injection or initial in-office infusion | |
| Cost | High list price; what you pay depends on insurance. Stelara biosimilars since 2025 | |
Final thoughts
In the Skyrizi vs Stelara decision there is no universal winner: the best option is the one your doctor chooses for your case, and then the one you can afford safely. If price is the barrier, we can help you understand your options with clear, pressure-free information.
Medical disclaimer. This article is informational and does not replace advice from a healthcare professional. We do not prescribe, sell, or dispense medications. Clinical and dosing decisions belong to your prescribing physician.
Sources
- Peyrin-Biroulet, L., et al. (2024). Risankizumab versus ustekinumab for moderate-to-severe Crohn’s disease. New England Journal of Medicine, 391(3), 213-223.
- U.S. Food and Drug Administration: Biosimilar product information.
- Provide Rx Health: Blog (providerxservices.com).
